The Promising Potential of Olezarsen: A Deep Dive into Ionis Pharmaceuticals' ESSENCE Study

Ionis Pharmaceuticals' recent announcement of positive topline results from the ESSENCE study represents a significant stride in the ongoing battle against atherosclerotic cardiovascular disease (ASCVD).